PATHELEN@ VULNEREX will be available worldwide in the second quarter of 2025. If you are interested, please register on our website and we will inform you as soon as possible about all details such as prices and availability.
Pathelen Health Care AG (PHC) is a Swiss company founded in 2014. PHC has developed the groundbreaking human wound care product PATHELEN® HYBRID, which is currently awaiting FDA 510(k) clearance in the US and MDR clearance in the EU. PHC's lead developer and founder, Mr. Andreas Tausch, and his research team set out to develop a medical device for the rapid and effective treatment of chronic wounds such as diabetic foot ulcers, pressure ulcers and venous leg ulcers.
Based on the scientific work of the late Dr. William Costerton, considered the father of biofilm, Mr. Tauch and his team identified biofilm as the main cause of these non-healing chronic wounds and focused all their efforts on the effective removal of biofilm without pharmacological ingredients and thus without side effects. PATHELEN® VULNEREX offers the same benefits.